BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.00
-0.25 (-0.95%)
Sep 8, 2026, 1:30 PM CST

BioGend Therapeutics Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-67.84-84.61-116.47-156.33-184.46-138.49
Depreciation & Amortization
49.3349.7751.1955.0253.1828.19
Loss (Gain) From Sale of Investments
------26.7
Loss (Gain) on Equity Investments
1.951.842.46-10.34-11.35
Stock-Based Compensation
96.163.64---
Provision & Write-off of Bad Debts
1.370.8----
Other Operating Activities
-19.82-20.17-13.02-13.1-29.26-5.81
Change in Accounts Receivable
-10.39-12.4-20.67-15.42-6.22-4.72
Change in Inventory
-11.23-4.560.58-11.654.131.38
Change in Accounts Payable
1.51-2.132.060.081.6-0.88
Change in Unearned Revenue
---2.5---
Change in Other Net Operating Assets
-1.11.64-16.1713.022.23-1.12
Operating Cash Flow
-47.23-63.66-98.91-138.72-168.78-136.8
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-2.93-1.87-0.65-26.04-18.18-0.67
Cash Acquisitions
-----26.41
Sale (Purchase) of Intangibles
---0.32--
Investment in Securities
-350100-6.24-64223.2-159.97
Other Investing Activities
-31.35-31.71-1.310.08-3.32-0.04
Investing Cash Flow
-384.2866.43-8.2-89.64201.7-134.27

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
--3.7-3.64-3.58-4.81-1.78
Lease Payments
-3.72-3.7-3.64-3.58-4.81-1.78
Net Debt Issued (Repaid)
-3.72-3.7-3.64-3.58-4.81-1.78
Issuance of Common Stock
360--400-289.63
Financing Cash Flow
356.28-3.7-3.64396.42-4.81287.85

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.53-0.2-0.74-1.19-0.79-0.49
Net Cash Flow
-75.77-1.12-111.49166.8727.3216.28

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-50.17-65.52-99.56-164.76-186.96-137.47
Free Cash Flow Growth
------
Free Cash Flow Margin
-21.20%-29.47%-59.38%-149.91%-594.54%-1483.13%
Free Cash Flow Per Share
-0.40-0.53-0.81-1.37-1.81-1.36
Levered Free Cash Flow
-24.27-32.15-57.11-95.39-98.09-83.82
Unlevered Free Cash Flow
-24.19-32.05-56.97-95.23-98.04-83.81
Free Cash Flow After Leases
-53.89-69.22-103.2-168.34-191.77-139.25

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.130.150.220.260.090.02
Cash Income Tax Paid
0.130.420.50.2-0.18-
Change in Working Capital
-21.22-17.44-26.7-13.97-8.25-5.34